Table 3 Patient subgroups that are more of less likely to receive targeted therapy while fulfilling SUTENT trial eligibility criteria
2008–2010 Cohort: mRCC at the initial diagnosis | 2011–2013 Cohort: mRCC | |||||||
|---|---|---|---|---|---|---|---|---|
Intermediate prognosis (n = 142) | Poor prognosis (n = 99) | Favourable/intermediate prognosis (n = 70) | Poor prognosis (n = 39) | |||||
No targeted therapy (n = 40) | Sunitinib (n = 102) | No targeted therapy (n = 29) | Sunitinib (n = 70) | No targeted therapy n = 25 | Sunitinib n = 45 | No targeted therapy n = 13 | Sunitinib n = 26 | |
Sex – n (%) | ||||||||
Female | NS | NS | NS | NS | 2 (8 %) | 15 (33 %) | NS | NS |
Male | NS | NS | NS | NS | 23 (92 %) | 30 (67 %) | NS | NS |
Median age – yr (range) | 71 (43–84) | 62 (23–89) | 71 (44–79) | 61 (39–79) | 72 (57–82) | 63 (42–79) | ||
Site of metastasis – n (%) | ||||||||
one | 25 (62 %) | 38 (37 %) | 15 (53 %) | 20 (29 %) | NS | NS | NS | NS |
more than one | 15 (38 %) | 64 (63 %) | 14 (47 %) | 50 (71 %) | NS | NS | NS | NS |
Neutrophil count – n (%) | ||||||||
normal | 27 (68 %) | 87 (85 %) | NS | NS | NS | NS | NS | NS |
> ULN | 13 (33 %) | 15 (15 %) | NS | NS | NS | NS | NS | NS |
Comorbidities | ||||||||
Zero or one | NS | NS | 15 (52 %) | 52 (74 %) | NS | NS | NS | NS |
More than one | NS | NS | 14 (48 %) | 18 (26 %) | NS | NS | NS | NS |